证券代码：300832 证券简称：新产业 公告编号：2023-074 深圳市新产业生物医学工程股份有限公司 授权公告日：2023年08月08日 专利权期限：20年（自申请日起算） 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 国家知识产权局颁发的2项《发明专利证书》，现将本次取得的发明专利具体情 况公告如下： 1、 发明名称：自动分析装置及抽液监控方法 专利号：ZL201810074886.2 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：胡毅、易万贯、尹力、张谭、汤俊辉、陈淑娟 专利申请日：2018年01月25日 上述专利保护技术为公司自主研发，应用于公司全自动化学发光免疫分析仪 器MAGLUMI X8。本发明涉及一种耗材盒提升机构，该提升机构通过分层支撑 耗材盒，并逐层带动多个耗材盒向上移动，使得提升机构底部耗材盒的加载动作 可以与提升机构内部耗材盒的传输动作同步进行，从而实现耗材盒的连续加载， 提高仪器的运行效率。 上述专利保护技术为公司自主研 ...

证券代码：300832 证券简称：新产业 公告编号：2023-073 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 | 序 | 产品名称 | 注册 | 注册证编号 | | | 注册证有效期 | | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | 分类 | | | | | | | | | | 1 | 总胆固醇测定试剂盒 （CHOD—PAP 法）注 | Ⅱ类 | 粤械注准 20232401324 | 2023 2028 | 年 年 | 08 08 | 月 月 | 08 07 日 | 日至 | 本试剂盒用于体外定量 测定人血清或血浆中总 | | | | | | | | | | | | 胆固醇（TC）的含量， | | | | | | | | | | | | 临床上主要用于高胆固 | | | | | | | | | | | | 醇血症的辅助诊断。 | | 2 | 甘油三酯测定试剂盒 （GPO—PAP 法）注 | Ⅱ类 | 粤械注准 202324 ...

证券代码：300832 证券简称：新产业 公告编号：2023-072 深圳市新产业生物医学工程股份有限公司 关于公司高级管理人员减持股份的预披露公告 公司高级管理人员丁晨柳保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 特别提示： 深圳市新产业生物医学工程股份有限公司（以下简称"公司"或"新产业"） 于近日收到公司高级管理人员丁晨柳出具的《关于股份减持计划的告知函》。 公司高级管理人员丁晨柳持有公司股份 812,600 股（占本公司总股本的 0.1034%），计划在本减持计划公告之日起 15 个交易日后的 6 个月内以集中竞价 交易方式减持本公司股份不超过 150,000 股（不超过本公司总股本的 0.0191%）； 若在本减持计划公告日至减持时间区间届满日期间公司有送股、资本公积金转增 股本等股份变动事项，减持股份数量进行相应调整。 一、股东的持股及拟减持数量情况 | 股东 | 持股数量 | 占公司总股 | 拟减持不超 | 拟减持股份 占其自身总 | 拟减持股份 占公司总股 | 备注 | | --- | - ...

证券代码：300832 证券简称：新产业 公告编号：2023-071 深圳市新产业生物医学工程股份有限公司 关于部分高级管理人员减持计划时间届满暨减持结果的公告 公司高级管理人员张蕾、丁晨柳、刘海燕保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 二、 减持计划的减持结果情况 本公司及董事会全体成员保证本公告内容与信息披露义务人提供的信息一 致。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于 2023 年 1 月 13 日披露了《关于持股 5%以上股东的一致行动人、部分高级管理人员减持 股份的预披露公告》（公告编号：2023-004，以下简称"减持计划"）。公司高 级管理人员张蕾、丁晨柳、刘海燕计划在减持计划公告之日起 15 个交易日后的 6 个月内以集中竞价交易方式分别减持本公司股份不超过 300,000 股、240,000 股、300,000 股（分别不超过本公司总股本的 0.0382%、0.0305%、0.0382%）。 若在减持计划公告日至减持时间区间届满日期间公司有送股、资本公积金转增股 本等股份变动事项，上述股东减持股份数量进行相应调整。 2023 ...

深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 1 证券代码：300832 证券简称：新产业 编号：2023-006 | --- | --- | --- | |----------|------------------|------------------------------------------------------------| | | | 投资者关系活动记录表 | | | □特定对象调研 | □分析师会议 | | 投资者关 | □媒体采访 | □业绩说明会 | | 系活动类 | □新闻发布会 | □路演活动 | | 别 | | | | | 现场参观 | | | | 其他 | 线上交流、国泰君安证券策略会、天风证券策略会 | | 参与单位 | | | | 名称及人 | 共计 57 家机构， | 84 名参会人员，详见附件《与会机构名单》。 | | 员姓名 | | | | 时间 | | 2023 年 7 月 3 日-7 月 25 日 | | 地点 | | 深圳市坪山区坑梓街道金沙社区锦绣东路 23 号新产业生物大厦等 | 董事长兼总经理 饶微 上市公司 接待人员 姓名 副总经理兼董事会秘 ...

深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 1 证券代码：300832 证券简称：新产业 编号：2023-005 | --- | --- | --- | |----------|------------------|------------------------------------------------------------| | | | 投资者关系活动记录表 | | | □特定对象调研 | □分析师会议 | | 投资者关 | □媒体采访 □ | 业绩说明会 | | 系活动类 | □新闻发布会 | □路演活动 | | 别 | | | | | 现场参观 | | | | 其他 | 线上交流、兴业证券策略会、长江证券策略会 | | 参与单位 | | | | 名称及人 | 共计 59 家机构， | 93 名参会人员，详见附件《与会机构名单》。 | | 员姓名 | | | | 时间 | | 2023 年 6 月 2 日-6 月 29 日 | | 地点 | | 深圳市坪山区坑梓街道金沙社区锦绣东路 23 号新产业生物大厦等 | 董事长兼总经理 饶微 上市公司 接待人员 姓名 副总经理兼董事会秘书 ...

深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 1 证券代码：300832 证券简称：新产业 编号：2023-004 深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|----------------------|------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 □ | 业绩说明会 | | 投资者关 | □新闻发布会 □ | 路演活动 | | 系活动类 | 现场参观 | | | 别 | | | | | 其他 | 线上交流、安信证券策略会、东北证券策略会、华安 | | | | 证券策略会、国盛证券策略会、中金证券策略会、国金证券策略 | | | | 会、汇丰前海证券策略会、华创证券策略会、国信证券策略会、 | | | 中信证券策略会 | | | 参与单位 | | | | 名称及人 | 共计 238 家机构， | 311 名参会人员，详见附件《与会机构名单》。 | | 员姓名 ...

Financial Performance - The company's revenue for Q1 2023 was ¥875,859,175.30, representing a 17.91% increase compared to ¥742,834,914.00 in the same period last year[4] - Net profit attributable to shareholders was ¥355,067,920.04, up 15.10% from ¥308,478,491.40 year-on-year[4] - The basic earnings per share increased to ¥0.4522, reflecting a growth of 15.18% compared to ¥0.3926 in the previous year[4] - The total profit reached CNY 405.50 million, an increase of 13.22% compared to the same period last year[16] - Net profit attributable to shareholders was CNY 355.07 million, reflecting a year-on-year growth of 15.10%[16] - Basic earnings per share for Q1 2023 were CNY 0.4522, compared to CNY 0.3926 in Q1 2022, marking an increase of 15.19%[25] Research and Development - Research and development expenses rose to ¥83,186,812.28, a 42.20% increase from ¥58,500,711.08, indicating a significant investment in innovation[8] - Research and development expenses increased to CNY 83,186,812.28, up 42.12% from CNY 58,500,711.08 in Q1 2022[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,257,771,027.56, a 3.47% increase from ¥7,014,554,339.23 at the end of the previous year[4] - Total assets reached CNY 7.26 billion, compared to CNY 7.01 billion at the start of the year[19] - The total assets of the company increased to CNY 7,257,771,027.56 from CNY 7,014,554,339.23 at the beginning of the year, reflecting a growth of 3.47%[21] - Total liabilities decreased to CNY 503,170,114.28 from CNY 615,059,771.67 at the beginning of the year, a reduction of 18.16%[21] - The company's total equity rose to CNY 6,754,600,913.28, up from CNY 6,399,494,567.56, reflecting an increase of 5.54%[21] Cash Flow - The net cash flow from operating activities was ¥179,610,145.96, slightly down by 0.56% from ¥180,613,025.70[4] - The cash inflow from operating activities amounted to $823,869,499.83, an increase of 25.5% compared to the previous period's $656,190,386.20[26] - The net cash flow from operating activities was $179,610,145.96, slightly down from $180,613,025.70 in the prior period[26] - The cash inflow from investment activities totaled $2,840,462,613.25, up from $2,696,896,831.85 in the previous period[27] - The net cash flow from investment activities was $41,107,370.59, a significant improvement from a negative $198,467,897.58 in the prior period[27] - Cash and cash equivalents at the end of the period amounted to CNY 699.75 million, up from CNY 483.43 million at the beginning of the year[18] - Cash and cash equivalents at the end of the period reached $699,418,197.44, compared to $594,982,055.18 at the end of the previous period[27] Market Performance - Domestic market revenue grew by 14.47% year-on-year, with a compound annual growth rate of 32.28% since Q1 2021[16] - Overseas market revenue increased by 24.81%, with instrument sales revenue growing by 49.25% year-on-year[16] - The company sold and installed 228 units of the fully automated chemiluminescence instrument MAGLUMI X8 during the reporting period[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,807, with the largest shareholder holding 26.86% of the shares[11] - The company has no changes in the number of restricted shares during the reporting period, maintaining a total of 501.50 million restricted shares[15] Other Financial Metrics - The weighted average return on equity was 5.40%, an increase of 0.06 percentage points from 5.34%[4] - The company reported a significant decrease in management expenses by 36.03%, from ¥32,611,716.84 to ¥20,861,130.81, due to the cessation of stock incentive expense accruals[8] - The total operating costs for Q1 2023 were CNY 510,265,240.29, which is an increase of 25.54% from CNY 406,434,035.81 in Q1 2022[22] - The company reported a profit before tax of CNY 405,499,268.85, up from CNY 358,136,631.30 in the previous year, indicating a growth of 13.19%[24] - Other comprehensive income after tax for Q1 2023 was CNY 38,425.68, compared to a loss of CNY 265,208.02 in Q1 2022[24] - The company received government subsidies amounting to ¥20,395,295.21, a 50.09% increase from ¥13,588,572.49 in the previous year[8] - The company reported a total of CNY 849.55 million in inventory, slightly up from CNY 839.33 million at the beginning of the year[19]

Financial Performance - In 2022, the company's operating revenue reached ¥3,046,955,734.50, representing a 19.70% increase from ¥2,545,415,315.72 in 2021[11]. - The net profit attributable to shareholders was ¥1,327,918,359.24, a 36.38% increase compared to ¥973,696,489.03 in 2021[11]. - The net profit after deducting non-recurring gains and losses was ¥1,240,605,226.60, up 40.52% from ¥882,878,837.06 in 2021[11]. - The net cash flow from operating activities was ¥962,391,435.81, reflecting a 24.47% increase from ¥773,218,330.43 in 2021[11]. - The total assets at the end of 2022 amounted to ¥7,014,554,339.23, a 14.33% increase from ¥6,135,507,556.27 at the end of 2021[11]. - The net assets attributable to shareholders increased to ¥6,399,494,567.56, up 14.03% from ¥5,611,998,691.33 in 2021[11]. - The company reported a basic earnings per share of ¥1.6907, a 36.13% increase from ¥1.2420 in 2021[11]. - The total revenue for 2022 reached CNY 3,046,955,734.50, representing a year-on-year increase of 19.70% from CNY 2,545,415,315.72 in 2021[58]. - The revenue from in vitro diagnostics accounted for 99.79% of total revenue, amounting to CNY 3,040,486,867.90, with a year-on-year growth of 19.74%[58]. - The gross margin for reagent products was 89.01%, while for instrument products it was 23.10%[59]. Market Expansion and Product Development - The company expects a compound annual growth rate of 15.38% in the Chinese in vitro diagnostic market from 2020 to 2025[19]. - The global in vitro diagnostic market size is projected to exceed $127.4 billion in 2022, with significant growth in emerging markets like China and India[18]. - The company has sold over 26,500 units of its fully automated chemiluminescence immunoassay analyzers globally, covering nearly 8,700 domestic medical terminals and reaching 151 countries and regions[23]. - The company has launched its first coagulation reagent product, obtaining domestic medical device registration, with a total of 3 coagulation diagnostic reagents registered[27]. - The company has developed four major technology platforms for in vitro diagnostic product research, including nanomagnetic microspheres and automated diagnostic instruments[27]. - The company is focusing on expanding its product line in cardiovascular and inflammatory disease diagnostics with several new reagents[44]. - The company is actively pursuing regulatory approvals for its innovative medical devices to enhance market presence and product offerings[43]. - The company has established a marketing network covering 151 countries and regions, with over 15,100 instruments sold overseas[53]. - The company is expanding its market presence, targeting new regions in Southeast Asia, aiming for a 10% market share by the end of the next fiscal year[107]. Research and Development - R&D expenses rose by 47.74% to ¥317,710,346.15, reflecting increased investment in research and development[65]. - The number of R&D personnel increased by 31.58% to 600, with the proportion of R&D staff rising to 21.29%[67]. - The company has implemented a systematic R&D management framework to enhance innovation capabilities and reduce R&D risks[95]. - The company is currently working on multiple instrument R&D projects, including the Biossays E6 Plus and Molecision R8, with some projects transitioning to production[48]. - The company plans to increase investment in new product development to achieve a strategy of "selling one generation, developing one generation, and reserving one generation" of products[104]. Corporate Governance and Compliance - The company established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management team since its establishment in August 2012[110]. - The board of directors has set up four specialized committees: the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee to ensure standardized operations and sustainable development[110]. - The company emphasizes investor relations management, utilizing various platforms for effective communication with investors[116]. - The company’s management compensation is directly linked to performance, promoting transparency and accountability[117]. - The company has committed to timely and accurate information disclosure obligations, particularly regarding stock reduction plans after the lock-up period[190]. Risk Management - The company emphasizes the importance of risk factors and countermeasures in its future development outlook, urging investors to pay attention[2]. - The company is adapting to the national medical insurance payment reform, which may impact pricing and sales volume in the in vitro diagnostic sector[24]. - The company faces risks related to policy changes, particularly in the context of centralized procurement reforms that could impact pricing and sales volumes[97]. - The company has established a risk management system for foreign exchange hedging, ensuring that all transactions are based on normal business operations[79]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 7.00 RMB per share (including tax) to all shareholders based on the total share capital as of the close of trading on the day of the dividend distribution announcement[2]. - The total cash dividend amount for 2022 is projected to be 550,288,434.50 RMB, based on a total share capital of 786,126,335 shares[161]. - The independent directors confirm the legality and compliance of the profit distribution plan, ensuring the protection of minority shareholders' interests[162]. - The company maintains a stable profit distribution policy, distributing cash dividends of 6 RMB per 10 shares for the 2021 fiscal year, with no stock dividends or capital reserve transfers[158]. Employee Management and Development - The total number of employees at the end of the reporting period is 2,818, including 2,798 in the parent company and 20 in major subsidiaries[153]. - The company has established a competitive salary and incentive system, combining short-term and long-term incentives to attract and retain talent[154]. - The training department was established in 2019, focusing on internal talent development and enhancing employee skills through various training programs[155]. - The company has a total of 6 PhD holders and 459 master's degree holders among its employees, reflecting a strong educational background within the workforce[153]. Environmental and Social Responsibility - The company implemented energy-saving measures, resulting in an 8% reduction in actual electricity consumption compared to expected usage in 2022[177]. - The company established a 100m³ concentrated water recovery pool, saving 8,859.5m³ of water resources in 2022 through the reuse of concentrated water[179]. - The company reduced paper consumption by 25% in 2022, promoting a paperless office initiative[181]. - The company actively participated in charitable donations to support poverty alleviation and rural revitalization, earning the title of "Caring Enterprise"[182].